Harvard Bioscience Inc. Common Stock (HBIO)

FairStock Score: 25/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits, generate cash, and carry little debt. Harvard Bioscience fails those tests. In fiscal 2025, the year ended 2025-12-31, revenue was $86.5 million and net income was -$56.7 million, or -$1.28 per diluted share. That follows fiscal 2024 revenue of $94.1 million and a net loss of $12.4 million, and fiscal 2023 revenue of $112.3 million and a net loss of $3.4 million. Revenue has fallen over those three years while losses widened. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, showed revenue of $22.7 million, up from $20.4 million in fiscal Q2 2025, but net income was still -$2.9 million. At the 2026-10-13 close of $8.27, FairStock's calculations show P/B 5.07, P/E -3.60, EV/EBITDA 44.25, FCF yield -4.9%, ROE -89.95%, Altman Z-Score -3.12, and Piotroski F-Score 4/9. The provided debt-to-equity is 5.96. Those are not marks of a durable moat or balance-sheet strength. A niche medical instruments business can be attractive, but this company has lost money in each of the last four years, so FairStock assigns no Lynch category. With a $37.6 million market cap and beta 1.53, it is small and volatile. At this price, I see speculation, not margin of safety. I would want sustained profits, positive free cash flow, and lower leverage before calling it a value opportunity.

In plain English: Harvard Bioscience sells specialized lab equipment and supplies used in life science research. The business looks weak: it has been losing money, has negative cash flow, and carries a lot of debt. At the 2026-10-13 close of $8.27, the price looks expensive relative to those weak profits and cash generation.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer